Rising demand for GLP-1 medications, Eli Lilly aims to meet challenges

From CNBC: 2024-06-17 09:00:01

Eli Lilly sees rising demand for Mounjaro and Zepbound medications. Outgoing CFO Anat Ashkenazi says company aims to meet supply challenges with new manufacturing plants. Some insurers reluctant to cover weight loss drugs due to cost concerns. Eli Lilly studying tirzepatide in patients with various health conditions. Medicare may cover obesity treatments with added health benefits. Society urged to view obesity as chronic disease.



Read more at CNBC: Eli Lilly CFO Anat Ashkenazi on managing soaring demand for GLP-1s